All In Biotech

Drug Trial Radar · NCT05211895

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 791 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

791

Actual

Start

Feb 18, 2022

Primary completion

Aug 10, 2026

Study completion Sep 8, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Arcus Biosciences, Inc.
First posted
Jan 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • DurvalumabDrug

    Durvalumab IV (Intravenous infusion)

  • DomvanalimabDrug

    Domvanalimab IV (Intravenous infusion)

  • PlaceboOther

    Placebo IV (Intravenous infusion)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Up to 5 years after randomization

Locations

226 sites in 28 countries. Site status is shown where the registry gives one.

  • Research Site

    Chandler, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Fountain Valley, California

  • Research Site

    Santa Rosa, California

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Jacksonville, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Saint Augustine, Florida

  • Research Site

    Macon, Georgia

  • Research Site

    Elmhurst, Illinois

  • Research Site

    Louisville, Kentucky

  • Research Site

    Baltimore, Maryland

  • Research Site

    Silver Spring, Maryland

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Detroit, Michigan

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Rochester, Minnesota

  • Research Site

    Reno, Nevada

  • Research Site

    East Brunswick, New Jersey

  • Research Site

    Columbus, Ohio

  • Research Site

    Maumee, Ohio

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Charleston, South Carolina

  • Research Site

    Chattanooga, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Fort Sam Houston, Texas

  • Research Site

    Fairfax, Virginia

  • Research Site

    Fort Belvoir, Virginia

  • Research Site

    Spokane Valley, Washington

  • Research Site

    Appleton, Wisconsin

  • Research Site

    Brussels, Belgium

  • Research Site

    Edegem, Belgium

  • Research Site

    Haine-Saint-Paul, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Sint-Niklaas, Belgium

  • Research Site

    Barretos, Brazil

  • Research Site

    Londrina, Brazil

Showing 40 of 226 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.